Literature DB >> 11398879

FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT.

C Franzius1, H E Daldrup-Link, J Sciuk, E J Rummeny, S Bielack, H Jürgens, O Schober.   

Abstract

BACKGROUND: The purpose was the comparison of positron emission tomography using F-18-fluorodeoxy-glucose (FDG-PET) and spiral thoracic CT to detect pulmonary metastases from malignant primary osseous tumors. PATIENTS AND METHODS: In 71 patients with histologically confirmed malignant primary bone tumors (32 osteosarcomas, 39 Ewing's sarcomas) 111 FDG-PET examinations were evaluated with regard to pulmonary/pleural metastases in comparison with spiral thoracic CT. Reference methods were the clinical follow-ups for 6-64 months (median 20 months) or a histopathologic analysis.
RESULTS: In 16 patients (23%) reference methods revealed a pulmonary/pleural metastatic disease. FDG-PET had a sensitivity of 0.50, a specificity of 0.98, and an accuracy of 0.87 on a patient based analysis. Comparable values for spiral CT were 0.75, 1.00, and 0.94. It was shown that no patient who had a true positive FDG-PET had a false negative CT scan, nor was a pulmonary metastases detected earlier by FDG-PET than by spiral CT.
CONCLUSIONS: There seems to be a superiority of spiral CT in the detection of pulmonary metastases from malignant primary bone tumors as compared with FDG-PET. Therefore, at present a negative FDG-PET cannot be recommended to exclude lung metastases. However, as specificity of FDG-PET is high, a positive FDG-PET result can be used to confirm abnormalities seen on thoracic CT scans as metastatic.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398879     DOI: 10.1023/a:1011111322376

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  45 in total

Review 1.  Diagnostic accuracy of ¹⁸F-FDG-PET and PET/CT in patients with Ewing sarcoma family tumours: a systematic review and a meta-analysis.

Authors:  Giorgio Treglia; Marco Salsano; Antonella Stefanelli; Maria Vittoria Mattoli; Alessandro Giordano; Lorenzo Bonomo
Journal:  Skeletal Radiol       Date:  2011-11-10       Impact factor: 2.199

2.  Has PET become an important clinical tool in paediatric imaging?

Authors:  Klaus Hahn; Thomas Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-05       Impact factor: 9.236

Review 3.  Clinical applications of molecular imaging in sarcoma evaluation.

Authors:  Rodney J Hicks; Guy C Toner; Peter F M Choong
Journal:  Cancer Imaging       Date:  2005-06-21       Impact factor: 3.909

4.  Is PET/CT necessary in paediatric oncology? For.

Authors:  Christiane Franzius; Kai Uwe Juergens; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

5.  A hybrid algorithm for PET/CT image merger in hybrid scanners.

Authors:  John A Kennedy; Ora Israel; Alex Frenkel; Rachel Bar-Shalom; Haim Azhari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-10       Impact factor: 9.236

6.  The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence.

Authors:  Andrea Angelini; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giulia Polverari; Giulia Trovarelli; Emanuela Palmerini; Stefano Ferrari; Stefano Fanti; Pietro Ruggieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

Review 7.  PET/CT in paediatric oncology: indications and pitfalls.

Authors:  Christiane Franzius; Kai Uwe Juergens
Journal:  Pediatr Radiol       Date:  2009-06

8.  Management of small pulmonary nodules in patients with sarcoma.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Rui Niimi; Takao Matsubara; Katsuyuki Kusuzaki; Masayuki Maeda; Tomoyasu Tagami; Atsumasa Uchida
Journal:  Clin Exp Metastasis       Date:  2009-05-23       Impact factor: 5.150

9.  What Is the Clinical Importance of Incidental Findings on Staging CT Scans in Patients With Sarcoma?

Authors:  Zachary Mayo; Sean Kennedy; Yubo Gao; Benjamin J Miller
Journal:  Clin Orthop Relat Res       Date:  2019-04       Impact factor: 4.176

10.  Targeted imaging of Ewing sarcoma in preclinical models using a 64Cu-labeled anti-CD99 antibody.

Authors:  Allison F O'Neill; Jason L J Dearling; Yuchuan Wang; Tanya Tupper; Yanping Sun; Jon C Aster; Monica L Calicchio; Antonio R Perez-Atayde; Alan B Packard; Andrew L Kung
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.